Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
| dc.contributor.author | Restrepo Valencia, Cesar A. | |
| dc.contributor.author | Aguirre Arango, Jose V. | |
| dc.contributor.author | Musso, Carlos G. | |
| dc.date.accessioned | 2020-01-17T14:39:23Z | |
| dc.date.available | 2020-01-17T14:39:23Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | In a high percentage of patients with chronic kidney disease (CKD) low levels of vitamin D are detected. The purpose of this study was to evaluate if the native vitamin D therapy (cholecalciferol) in the patients with stage 3 and hypovitaminosis D allows to modify markers of bone and mineral metabolism once normal serum levels have been achieved. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.issn | 11787058 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/4533 | |
| dc.language.iso | eng | eng |
| dc.publisher | Dovepress | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | eng |
| dc.source | International Journal of Nephrology and Renovascular Disease | eng |
| dc.source | Vol. 12 (2019) | |
| dc.source.uri | https://doi.org/10.2147/IJNRD.S214194 | |
| dc.subject | Vitamin D | eng |
| dc.subject | Cholecalciferol | eng |
| dc.subject | Chronic kidney disease | eng |
| dc.subject | Hypovitaminosis D | eng |
| dc.title | Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America | eng |
| dc.type | article | eng |
| dcterms.references | Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8–F28. doi:10.1152/ajprenal.00336.2004 | eng |
| dcterms.references | Jones G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu Rev Nutr. 2013;33:10.1–10.22. doi:10.1146/annurev-nutr-071812-161203 | eng |
| dcterms.references | Michigami T. Update on recent progress in vitamin D research. Vitamin D metabolism and its regulation. Clin Calcium. 2017;27:1517–1523. doi:10.CliCa171115171523 | eng |
| dcterms.references | Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. doi:10.1016/j.kisu.2017.04.001 | eng |
| dcterms.references | Restrepo VCA, Aguirre AJV. Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2–5. Colomb Med (Cali). 2016;47: 160–166. doi:10.25100/cm.v47i3.2148 | eng |
| dcterms.references | Restrepo VCA, Aguirre AJV, Caceres ED. Determination of vitamin D (25(OH)D) levels in renal transplant patients and their importance in accordance with the glomerular filtration rate. Rev Colomb Reumatol. 2018;25:161–168. | eng |
| dcterms.references | Gluba-Brzozka A, Franczyk B, Cialkowska-Rysz C, Olszewski R, Rysz J. Impact of vitamin D on the cardiovascular system in advance chronic kidney disease (CKD) and dialysis patients. Nutrients. 2018;10:6: 709. doi:10.3390/nu10060709 | eng |
| dcterms.references | Zhang Y, Darssan D, Pascoe EM, Johnson DW, Pi H, Dong J. Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. Nephrol Dial Transplant. 2018;33:1742–1751. doi:10.1093/ndt/gfy016 | eng |
| dcterms.references | Liu M, Wang J, He Y. Serum 25-Hydroxyvitamin D were associated with higher risk of both albuminuria and impaired GFR incidence: a cohort study based on CLHLS study. BMC Nephrol. 2019;20:20. doi:10.1186/s12882-019-1202-8 | eng |
| dcterms.references | Molina P, Gorriz JL, Molina MD, et al. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol. 2016;5:471–481. doi:10.5527/wjn.v5.i5.471 | eng |
| dcterms.references | Eknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202. doi:10.1016/S0272- 6386(03)00905-3 | eng |
| dcterms.references | KDIGO. Clinical practice for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD). Kidney Int. 2009;76(suppl 113):S1–S130. | eng |
| dcterms.references | Alola JF. Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab. 2011;96:2987–2996. doi:10.1210/jc.2011-0090 | eng |
| dcterms.references | Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–856. doi:10.1093/ajcn/ 69.5.842 | eng |
| dcterms.references | Lee JP, Tansey M, Jetton JG, Krasowski MD. Vitamina D toxicity: a 16 year retrospective study at an academic medical center. Lab Med. 2018;21:123–129. doi:10.1093/labmed/lmx077 | eng |
| dcterms.references | Etayo HE, Restrepo CA. Acute tubular necrosis due to hypercalcemia secondary to vitamin D toxicity. Acta Med Colomb. 2010;35:99–102. | eng |
| dcterms.references | Garcia CA, Holguin MC, Caceres D, Restrepo CA. Importance of hyperphosphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev Colomb Nefrol. 2017;4:24–41. | eng |
| dcterms.references | Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67:929–936. doi:10.1210/jcem-67-5-929 | eng |
| dcterms.references | Toussaint ND, Damasiewicz MJ. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the arms? Nephrology (Carlton). 2017;22 (Suppl 2):51–56. doi:10.1111/nep.13026 | eng |
| dcterms.references | Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. doi:10.7326/0003-4819-145-4-200608150-00004 | eng |
| dcterms.references | Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716. doi:10.1007/s00198-005-1867-7 | eng |
| dcterms.references | Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–1154. doi:10.1007/s00198-010-1285-3 | eng |
| dcterms.references | American geriatrics society workgroup on vitamin D supplementation for older adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for prevention of falls and their consequences. J Am Geriatr Soc. 2014;62:147–152. doi:10.1111/jgs.12631 | eng |
| dcterms.references | Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol. 2007;103:620–625. doi:10.1016/j.jsbmb.2006.12.076 | eng |
| dcterms.references | Fuleihan GE-H. Vitamin D deficiency in the Middle East and its health consequences for children and Adults. Clinic Rev Bone Miner Metab. 2009;7:77–93. doi:10.1007/s12018-009-9027-9 | eng |
| dcterms.references | Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20: 1807–1820. doi:10.1007/s00198-009-0954-6 | eng |
| dcterms.references | Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930. doi:10.1210/jc.2011- 0385 | eng |
| dcterms.references | Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439–443. doi:10.1007/s001980050030 | eng |
| dcterms.references | Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88:185–191. doi:10.1210/jc.2002- 021064 | eng |
| dcterms.references | Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997;65:67–71. doi:10.1093/ajcn/ 65.1.67 | eng |
| dcterms.references | Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58. doi:10.1210/jc.2010-2704 | eng |
| dcterms.references | Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305–312. doi:10.1359/jbmr. 090728 | eng |
| dcterms.references | Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease stages 2–5 and on dialysis. European society for paediatric nephrology chronic kidney disease mineral and bone disorders and dialysis working groups. Nephrol Dial Transplant. 2017;32: 1098–1113. doi:10.1093/ndt/gfx065 | eng |
| dcterms.references | Shroff R, Wan M, Gullett A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol. 2012;7:216–223. doi:10.2215/CJN.04760511 | eng |
| dcterms.references | Krause R, Roth HJ, Kaase H, Stange R, Holick MF. Vitamin D status in chronic kidney disease – UVB irradiation is superior to oral supplementation. Anticancer Res. 2016;36:1397–1401. | eng |
| dcterms.references | KDOQI WG. K/DOQI clinical practice guidelines for nutrition in children with CKD. Am J Kidney Dis. 2009;53:S11–S104. | eng |
| dcterms.references | Fried C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2017;10:109–122. doi:10.2147/IJNRD. S97637 | eng |
| dcterms.references | Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672–679. doi:10.3945/ajcn.112.040642 | eng |
| dcterms.references | Westerberg P-A, Sterner G, Ljunggren O, et al. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3–4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant. 2018;33:466–471. doi:10.1093/ ndt/gfx059 | eng |
| dcterms.references | Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease. J Bone Miner Res. 2018;33:404–409. doi:10.1002/jbmr.v33.3 | eng |
| dcterms.references | Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50:59–68. doi:10.1053/j.ajkd.2007.04.010 | eng |
| dcterms.references | Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27:36–43. doi:10.1159/000098561 | eng |
| dcterms.references | Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of high vs conventional ergocalciferol dose for increasing 25- hydroxyvitamin D and suppressing parathyroid hormone levels in stage III–IV CKD with vitamin D deficiency/insufficiency: a randomized controlled trial. J Med Assoc Thai. 2015;98:643–648. | eng |
| dcterms.references | Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systemic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–1364. doi:10.3945/ajcn.111.031070 | eng |
| dcterms.references | Wetmore JB, Kimber C, Mahnken JD, Stubbs JR. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Br J Nutr. 2016;116:2074–2081. doi:10.1017/S000711451600427X | eng |
| dcterms.references | Tripkovic L, Wilson LR, Hart K, et al. Daily supplementation with 15 ug vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12 wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr. 2017;106:481–490. doi:10. 3945/ajcn.116.138693 | eng |
| dcterms.references | Oliveri B, Mastaglia SR, Brito GM, et al. Vitamin D3 seems more appropiate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. Eur J Clin Nutr. 2015;69:697–702. doi:10.1038/ejcn.2015.16 | eng |
| dcterms.references | Chao YS, Brunel L, Faris P, Veugelers PJ. The importance of dose, frequency and duration of vitamin D supplementation for plasma 25-hydroxyvitamin D. Nutrients. 2013;5:4067–4078. doi:10.3390/ nu5104067 | eng |
| dcterms.references | Mager D, Jackson ST, Hoffmann M, Jindal K, Senior PA. Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: results of an open label randomized clinical trial. Clin Nutr. 2017;36:686–696. doi:10.1016/j.clnu.2016. 05.012 | eng |
| dcterms.references | Bover J, Egido J, Fernandez-Giraldez E, et al. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. Nefrologia. 2015;35:28–41. doi:10.3265/ Nefrologia.pre2014.Sep.11796 | eng |
| dcterms.references | Melamed ML, Chonchol M, Gutierre OM, et al. The role of vitamin D in CKD stages 3 to 4: report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis. 2018;72:834–845. doi:10.1053/j.ajkd.2018.06.031 | eng |